Syndax Pharmaceuticals Inc.

News & Events

Press Releases

In The Media

1. Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

   GlobeNewswire JUN 24, 2025 4:01 PM EDT
   – PDUFA action date set for October 25, 2025 – – sNDA being revi...
   READ ARTICLE

2. Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

   GlobeNewswire JUN 12, 2025 12:02 PM EDT
   – Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in old...
   READ ARTICLE

3. Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

   GlobeNewswire JUN 12, 2025 7:00 AM EDT
   – 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML ...
   READ ARTICLE

4. Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

   GlobeNewswire JUN 5, 2025 4:01 PM EDT
   NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX ), a commerc...
   READ ARTICLE

5. Syndax Announces Participation in June Investor Conferences

   GlobeNewswire MAY 29, 2025 7:00 AM EDT
   NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-st...
   READ ARTICLE

6. Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo(TM) (axatilimab-csfr)

   GlobeNewswire MAY 14, 2025 9:30 AM EDT
   – Revumenib abstracts highlight compelling results in acute leukemia across the frontline ...
   READ ARTICLE

7. Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

   GlobeNewswire MAY 12, 2025 4:01 PM EDT
   - Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leadin...
   READ ARTICLE

8. Syndax Announces Participation in May Investor Conferences

   GlobeNewswire MAY 8, 2025 7:00 AM EDT
   NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-st...
   READ ARTICLE

9. Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

   GlobeNewswire MAY 7, 2025 4:01 PM EDT
   – Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT...
   READ ARTICLE

10. Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

    GlobeNewswire MAY 5, 2025 4:01 PM EDT
    – $20.0 million in Revuforj ® (revumenib) net revenue in first full quart...
    READ ARTICLE